Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: David M. Evans who wrote (260)	5/8/1998 11:18:00 AM
From: Junehee Lee	Read Replies (2) \| Respond to of 705

I guess that something is really up for the company. Anyone knows what? Regards, J

To: David M. Evans who wrote (260)	5/8/1998 2:20:00 PM
From: Marty	Respond to of 705

Dave, It isn't an "either/or" (hype vs science) situation. I don't think having one excludes the other and you could and should have both ... good investor relations and good science. I NEVER asked for hype. NEOT certainly doesn't need any hype. It does need to tell its story. Is it possible for you to describe what is in the latest NeuroInvestment newsletter? As far as I can tell, whatever he said MAY be responsible for the recent price increase. As I recall, NeuroInvest wasn't given a "short shrift" and certainly not for not hyping the stock. He was unnecessarily derogatory ("mom and pop operation") and did not give NEOT any credit at all for what it had... positive impressive animal (and some human) test results and at least a year's head start over all competitors in testing the drug in human tests. Asking for news is not asking for "hype" and shareholders are certainly entitled to say positive things about the company and defend it from unfair comments. None of this is hype and there is quite a bit more the company could and should do in public relations before it approaches ANYTHING like hype. Nobody likes staggering around in the dark when there would be know no harm in shedding a little light on the status. Maybe NeuroInvest knows something we don't.